Biota Pharmaceuticals Inc

Type: Company
Name: Biota Pharmaceuticals Inc
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Alert: Biota Pharmaceuticals Inc (NASDAQ:BOTA) Faces Investor Investigation

San Diego, CA -- (SBWIRE) -- 08/19/2014 -- An investigation on behalf of investors of Biota Pharmaceuticals Inc (NASDAQ:BOTA) shares over potential securities laws violations by Biota Pharmaceuticals and certain of its directors and officers in connection ... [Published CEOWorld Magazine - Aug 19 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

GenMark Diagnostics names Dr James Fox as board chair

Molecular diagnostic company GenMark Diagnostics (NasdaqGM:GNMK) revealed on Monday the election of Dr James Fox as its new board chairman, replacing the outgoing Christopher Gleeson. Dr Fox has been a member of the company's board since September 20 ... [Published Individual.com - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 2 reports

TAXIS acquires novel antimicrobial drug candidates from Biota

TAXIS Pharmaceuticals, Inc. (the "Company") today announced the acquisition of a group of novel antimicrobial drug candidates from Biota Pharmaceuticals Inc. ("Biota") of Atlanta, GA. The acquisition will help expand the Company's ongoing research into ... [Published News-Medical.Net - Aug 11 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Biota Pharma announces positive results from phase 2 IGLOO trial of laninamivir octanoate

Biota Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced top-line data from a randomised, double-blind, ... [Published PharmaBiz - Aug 05 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Biota's Flu Drug Fails Mid-Stage Study

Reuters Health InformationBy Reuters StaffAugust 04, 2014(Reuters) - Biota Pharmaceuticals Inc said its experimental influenza drug failed to meet the main goal in a mid-stage study.Two doses of the drug, laninamivir octanoate, were being tested against ... [Published Diabetes Care - Aug 04 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Benzinga's Top Downgrades

Analysts at Deutsche Bank downgraded Diamond Offshore Drilling (NYSE: DO) from Hold to Sell. The target price for Diamond Offshore Drilling has been lowered from $60.00 to $34.00. Diamond Offshore Drilling's shares closed at $47.32 on Friday.Barclays ... [Published Benzinga.com - Aug 04 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 2 reports

Phase II Failure Casts Shadow Over Biota Flu Drug

Related Biotechnology, Pharmaceutical and Healthcare NewsBiota Pharmaceuticals has said its laninamivir influenza A and B drug failed a Phase II international clinical trial comparing it with placebo, and that it has no plans to develop it independently ... [Published BioPortfolio - Aug 04 2014]
First reported Aug 01 2014 - Updated Aug 02 2014 - 12 reports

News Scan for Aug 01, 2014

Poor phase 2 results lead Biota to suspend flu drug laninamivirThe neuraminidase inhibitor laninamivir, made by Biota Pharmaceuticals Inc. of Alpharetta, Ga., failed to perform better than a placebo at alleviating influenza symptoms in a phase 2 trial, ... [Published Centre For Infectious Disease Research and Policy - Aug 02 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

LinkedIn Corp (LNKD) Gets a Boost on Results, Revamped Software

BioTelemetry, Inc. (NASDAQ: BEAT ), LinkedIn Corp (NYSE: LNKD ) and Spirit AeroSystems Holdings, Inc. (NYSE: SPR ) are this Friday’s top gainers midday. On the losing end are Community Health Systems (NYSE: CYH ), Biota Pharmaceuticals Inc (NASDAQ: BOTA ... [Published Value Walk - Aug 01 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 3 reports

BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota Pharmaceuticals, Inc.

First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Morning Market Losers

Vocera Communications (NYSE: VCRA) shares dropped 26.09% to $9.29 after the company reported Q2 results and appointed Justin Spencer as Executive Vice President and Chief Financial Officer.ServiceSource International (NASDAQ: SREV) shares declined 26.07% ... [Published Benzinga.com - Aug 01 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

3 Biotech Stocks Under $10 in Breakout Territory

DELAFIELD, Wis. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.Stocks that are making large moves like these are favorites among short-term traders because they ... [Published West Hartford News - Jul 30 2014]

Quotes

...spectrum of the emerging, drug-resistant pathogens that are a well-known and growing public healthhealth threat," said Gregory Mario, CEO of TAXIS. "When combined with our proprietary technology, the compounds appear to be effective against the two types of drug-resistant staph infections that most concern health care providers."
...in the time to alleviate patient-reported influenza symptoms," stated Russell H Plumb, the company's president and chief executive officer, "We expect to complete a full analysis of additional clinical, safety, and pharmacokinetic data forthcoming from this trial over the next several months; however, at this time we do not have any plans to independently advance the development of LANI for the treatment of influenza and intend to evaluate next steps for the LANI programme outside of Japan with our partner, Daiichi Sankyo."
The ECDC concluded in a news release, "Control of gonorrhoea relies on effective antimicrobial treatment. If existing agents would become less efficient the impact would be significant: with more than 47,000 reported cases in 2012, gonorrhoea is the second most frequently recorded sexually transmitted infection in Europe after chlamydia."
"We expect to complete a full analysis of additional clinical, safety, and pharmacokinetic data forthcoming from this trial over the next several months" Plumb said in a statement...

More Content

All (43) | News (32) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (9)
sort by: Date | Relevance
Alert: Biota Pharmaceuticals Inc (NASDAQ:BOTA) ... [Published CEOWorld Magazine - Aug 19 2014]
GenMark Diagnostics names Dr James Fox as board... [Published Individual.com - Aug 12 2014]
GenMark Diagnostics Appoints Dr. James Fox as C... [Published TVNewsCheck - Aug 11 2014]
TAXIS acquires novel antimicrobial drug candida... [Published News-Medical.Net - Aug 11 2014]
TAXIS Pharmaceuticals Expands Research Portfolio [Published Newswise - Aug 11 2014]
Biota Pharma announces positive results from ph... [Published PharmaBiz - Aug 05 2014]
Biota's Flu Drug Fails Mid-Stage Study [Published Diabetes Care - Aug 04 2014]
Benzinga's Top Downgrades [Published Benzinga.com - Aug 04 2014]
Research Analysts’ Downgrades for August, 4th (... [Published American Banking News - Aug 04 2014]
Phase II Failure Casts Shadow Over Biota Flu Drug [Published BioPortfolio - Aug 04 2014]
Phase II Failure Casts Shadow Over Biota Flu Drug [Published Health News Daily - Aug 04 2014]
CEL-SCI's Phase III Head and Neck Cancer Trial ... [Published BioMedReports - Aug 02 2014]
News Scan for Aug 01, 2014 [Published Centre For Infectious Disease Research and Policy - Aug 02 2014]
Biota's lead drug fails mid-stage study, shares... [Published DailyMe.Com - Aug 01 2014]
LinkedIn Corp (LNKD) Gets a Boost on Results, R... [Published Value Walk - Aug 01 2014]
Biota Pharmaceuticals, Inc. Stock Crashes As In... [Published BioSpace - Aug 01 2014]
Biota tanks as its flu drug comes up empty in P... [Published FierceBiotech - Aug 01 2014]
Biota’s disappointing flu medicine no bettter t... [Published MedCity News - Aug 01 2014]
Biota shares slump after flu drug fails Phase 2... [Published Seeking Alpha - Aug 01 2014]
BIOTA ALERT: Shareholder Rights Law Firm Johnso... [Published Digital Journal - Aug 01 2014]
Morning Market Losers [Published Benzinga.com - Aug 01 2014]
UPDATE 2-Biota's lead drug fails mid-stage stud... [Published CNBC - Aug 01 2014]
BIOTA ALERT: Shareholder Rights Law Firm Johnso... [Published TheStreet.com - Aug 01 2014]
BIOTA ALERT: Shareholder Rights Law Firm Johnso... [Published Business Wire Professional Services News - Aug 01 2014]
Daiichi Sankyo, Biota's laninamivir fails to me... [Published FirstWord Pharma - Aug 01 2014]
Biota Pharma Reports Top-line Data From Laninam... [Published RTTNews.com - Aug 01 2014]
UPDATE 1-Biota's flu drug fails mid-stage study [Published CNBC - Aug 01 2014]
Biota Reports Top-Line Data From Its Phase 2 "I... [Published GlobeNewswire: Acquisitions News - Aug 01 2014]
Biota's influenza drug fails in mid-stage study [Published CNBC - Aug 01 2014]
Biota Reports Top-Line Data From Its Phase 2 "I... [Published Stock Nod - Aug 01 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BIOTA ALERT: Shareholder Rights Law Firm Johnso... [Published Business Wire Professional Services News - Aug 01 2014]
SAN DIEGO--(BUSINESS WIRE)--BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota Pharmaceuticals, Inc ...
Research and Markets: Biota Pharmaceuticals, In... [Published Business Wire Health News - Jun 04 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/965h3w/biota) has announced the addition of the "Biota Pharmaceuticals, Inc. - Product Pipeline Review - 2014" company profile to their offering. This report provides ...
1

Press Releases

sort by: Date | Relevance
Biota Reports Top-Line Data From Its Phase 2 "I... [Published GlobeNewswire: Acquisitions News - Aug 01 2014]
Biota Announces Restructuring Plan [Published GlobeNewswire: Advertising News - Jun 02 2014]
34% Drop in Biota Pharmaceutical, Inc.'s Stock ... [Published Financial Services - May 12 2014]
Faruqi & Faruqi, LLP Encourages Investors Who S... [Published Financial Services - May 10 2014]
Biota Provides Update on BARDA Contract for Lan... [Published GlobeNewswire: Advertising News - May 08 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.